Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
暂无分享,去创建一个
[1] G. Morgan,et al. Guidelines for the diagnosis and management of multiple myeloma 2011 , 2011, British journal of haematology.
[2] Diane Warren,et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.
[3] Robert A Kyle,et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.
[4] J. Willey,et al. Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas , 2005, Molecular Cancer.
[5] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[6] D. Crouch,et al. Inactivation of MAP kinase signalling in Myc Transformed Cells and Rescue by LiCl inhibition of GSK3 , 2005, Molecular Cancer.
[7] Shaomeng Wang,et al. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. , 2005, Molecular cancer therapeutics.
[8] Shaomeng Wang,et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. , 2005, Molecular cancer therapeutics.
[9] Shaomeng Wang,et al. In vitro Effects of the BH3 Mimetic, (−)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells , 2004, Clinical Cancer Research.
[10] L. Chiang,et al. Upregulation of Fas/Fas ligand‐mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line , 2004, Clinical and experimental pharmacology & physiology.
[11] D. Hou,et al. Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. , 2004, Archives of biochemistry and biophysics.
[12] M. Linden,et al. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. , 2004, Blood.
[13] M. Ergun,et al. Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K‐562 cells , 2004, Cell biology international.
[14] John Calvin Reed,et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.
[15] Dajun Yang,et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. , 2003, Biochemical pharmacology.
[16] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[17] Y. Gazitt,et al. Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. , 2003, Blood.
[18] A. Kudelka,et al. An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. , 2002, Pharmacological research.
[19] I. Enyedy,et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.
[20] C. Hudis,et al. Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial , 2001, Breast Cancer Research and Treatment.
[21] P. Groundwater,et al. Structure-activity studies on gossypol in tumor cell lines , 2000, Anti-cancer drugs.
[22] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[23] M. Reidenberg,et al. Gossypol Treatment of Recurrent Adult Malignant Gliomas , 1999, Journal of Neuro-Oncology.
[24] John C Reed,et al. Bcl-2 family proteins , 1998, Oncogene.
[25] S. Cory,et al. The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.
[26] C. Thompson,et al. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. , 1998, Trends in cell biology.
[27] M. Shelley,et al. Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines , 1997, Melanoma research.
[28] S. Grant,et al. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. , 1994, Cancer research.
[29] R. Knazek,et al. Oral gossypol in the treatment of metastatic adrenal cancer. , 1993, The Journal of clinical endocrinology and metabolism.
[30] L. Larsson,et al. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. , 1992, Blood.
[31] J. Jaroszewski,et al. Action of gossypol and rhodamine 123 on wild type and multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear magnetic resonance and toxicity studies. , 1990, Cancer research.
[32] F. W. Cox,et al. Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. , 1990, Molecular pharmacology.
[33] R. Knapp,et al. Antiproliferative effect of gossypol and its optical isomers on human reproductive cancer cell lines. , 1989, Gynecologic oncology.
[34] L. Zech,et al. Cytogenetic studies on human myeloma cell lines , 1987, International journal of cancer.
[35] S. Korsmeyer,et al. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. , 1987, The Journal of clinical investigation.
[36] M. Oken,et al. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. , 1987, The New England journal of medicine.
[37] G. Tuszynski,et al. Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. , 1984, Cancer research.
[38] Shaomeng Wang,et al. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. , 2005, Molecular cancer therapeutics.
[39] S. Rosati,et al. Bcl-xl expression in multiple myeloma , 2005, Medical oncology.
[40] J. Winfield,et al. In vitro andin vivo cytotoxicity of gossypol against central nervous system tumor cell lines , 2005, Journal of Neuro-Oncology.
[41] R. Coombes,et al. A preliminary clinical study of gossypol in advanced human cancer , 2004, Cancer Chemotherapy and Pharmacology.
[42] S. Kulp,et al. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. , 2004, Anticancer research.
[43] R. Mohammad,et al. Small-molecule inhibitors of Bcl-2 protein , 2004 .